PubMed Health⌕ Search

Biomedical subjects

E Bernal Morell

Publications and source records attributed to E Bernal Morell.

4 recordsLinked to original sources

[Systemic embolism after reversion to sinusal rhythm of persistent atrial flutter].

BACKGROUND: The incidence of embolism in atrial flutter has been underestimated in the routine clinical practice. PATIENTS AND METHODS: In this study the incidence of thromboembolic events after restoration of sinus rhythm (by catheter ablation or cardioversion) was compared in two groups of consecutive patients, with a different anticoagulation protocol. A total of 169 patients were evaluated. A first retrospective analysis of 79 non anticoagulated patients (group I). A second prospective group of 90 patients who were treated with an anticoagulation protocol (group II) similar to that for patients with atrial fibrillation. All had typical atrial flutter of at least one month's duration before the procedure. RESULTS: The mean age of patients in group I was 61 12 years and the mean left ventricular ejection fraction was 57 6%. Patients in group II had a mean age of 61 10 years and the mean left ventricular ejection fraction was 56 9%. No differences were observed regarding prevalence of structural cardiopathy, arterial hypertension, diabetes mellitus, left ventricular dysfunction, atrial size or atrial fibrillation between the two groups of patients. Four patients in the retrospective analysis (5%) had an embolic event associated with the procedure, compared with 0 (0%) in the group of patients treated with the anticoagulation protocol. The efficient anticoagulation was associated with a lower risk of thromboembolic events (p < 0.05). CONCLUSIONS: The incidence of embolic events after reversion to sinusal rhythm of persistent atrial flutter can be decreased. These patients should follow the same recommendations of anticoagulation that apply for patients with persistent atrial fibrillation that are going to be reverted to sinus rhythm.

Anticoagulants↗

[Nodular alveolar pattern of presentation for amiodarone pulmonary toxicity].

Amiodarone is a triiodinated antiarrhythmic drug that accumulates in alveolar macrophages. Its use is limited by its high rate of associated pulmonary toxicity, estimated at 5-7%. Radiologic findings for pulmonary toxicity caused by amiodarone are unspecific and varied. The most common finding is subpleural reticular-type interstitial thickening, predominately in the bases of the lungs. However, the presence of parenchymal nodules is an uncommon presentation. We report the case of a woman treated with amiodarone that presented multiple nodular lesions at plain-film radiography and high-resolution CT that were compatible with pulmonary toxicity caused by amiodarone at pathologic examination.

Aged↗